# KQ Labs

> KQ Labs is a VC fund in London backing Health Care, Medical Device and SaaS. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 8
- Last investment: Jan 2025
- Lead investor: 0%
- Last updated: Aug 2026
- X (Twitter): https://twitter.com/KQLabs
- Website: http://www.knowledgequarter.london/kq-labs/

KQ Labs is a VC fund in London focused on Health Care and Medical Device. The KQ Labs accelerator is a 16-week programme that offers startup founders access to capital and other vital resources. The programme will help early-stage data-driven startup founders to validate their ideas and put their startups on a path to receive further investment from Government grants, venture capital and other sources.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 38% |
| Medical Device | 2 | 25% |
| SaaS | 1 | 13% |
| Software | 1 | 13% |
| Fertility | 1 | 13% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Pre-Seed | 4 | 50% |
| Seed | 2 | 25% |
| Convertible Note | 2 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 5 | 63% |
| United States | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EnhancedDx | EnhancedDx unblocks each stage of the patient pathway and helps clinicians make decisions most likely to result in positive outcome We reduce the time to treatment from 3 years to 30 days with at-home testing, remote diagnostics, and AI-enabled care. To learn more, please visit our website. | $50.1K | Convertible Note | Jan 01, 2025 |  |
| Juniver | Juniver provides on-demand help, specialized care, and a supportive network for long-term recovery from eating disorders. | $1.2M | Pre-Seed | Oct 21, 2023 |  |
| Proxximos | Our products track where pathogens may have spread, enabling rapid and accurate action to prevent them infecting the next host. |  | Pre-Seed | Nov 08, 2022 |  |
| Exogene | Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M | Pre-Seed | Apr 25, 2022 |  |
| Exogene | Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M | Seed | Apr 25, 2022 |  |
| Neurovirt | Immersive Virtual Reality for gamification and quantification of movement rehabilitation | $54.6K | Convertible Note | Nov 01, 2021 |  |
| Concr | ConcR’s software integrates a breadth of data into a model to predict how and why a cancer therapy will behave | $691.5K | Pre-Seed | Apr 01, 2021 |  |
| Concr | ConcR’s software integrates a breadth of data into a model to predict how and why a cancer therapy will behave | $654K | Seed | Apr 01, 2021 |  |

8 of 8 investments shown.

## Co-investors
- [R42 Group](https://shizune.co/investors/profile/r42-group) — VC Fund, 4 deals together
- [Avonmore Developments](https://shizune.co/investors/profile/avonmore-developments) — VC Fund, 3 deals together
- [Accelerate@Babraham](https://shizune.co/investors/profile/accelerate-babraham) — VC Fund, 2 deals together
- [Cambridge Angels group](https://shizune.co/investors/profile/cambridge-angels-group) — VC Fund, 2 deals together
- [Deep Science Ventures](https://shizune.co/investors/profile/deep-science-ventures) — VC Fund, 2 deals together
- [Illumina](https://shizune.co/investors/profile/illumina) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

## FAQ

### What does KQ Labs invest in?

KQ Labs invests primarily in Health Care, Medical Device and SaaS startups, most often at Pre-Seed and Seed stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did KQ Labs last invest?

The most recent investment recorded for KQ Labs closed in Jan 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co